Scilex Holding (SCLX) Cash & Equivalents (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Cash & Equivalents of $144.9 million for Q1 2026, up 2397.81% year-over-year from $5.8 million in Q1 2025, and up 2823.77% quarter-over-quarter from $5.0 million in Q4 2025.
Scilex Holding (SCLX) Cash & Equivalents (2020 - 2026) Analysis & Trends
Scilex Holding's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $144.9 million for Q1 2026.
- In Q1 2026, Cash & Equivalents rose 2397.81% year-over-year to $144.9 million; the TTM figure through Mar 2026 stood at $144.9 million (up 2397.81% YoY), while the FY2025 annual figure was $5.0 million, up 51.44% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $144.9 million, up from $5.0 million in the prior quarter.
- The five-year high for Cash & Equivalents was $144.9 million in Q1 2026, with the low at $34961.0 in Q3 2022.
- The 5-year median for Cash & Equivalents is $3.3 million (2024), against an average of $13.0 million.
- The sharpest annual moves came in 2023 and 2024: Cash & Equivalents surged 9607.58% in 2023, then plunged 96.06% in 2024.
- Scilex Holding's Cash & Equivalents stood at $2.2 million in 2022, then jumped by 79.53% to $3.9 million in 2023, then slipped by 16.55% to $3.3 million in 2024, then surged by 51.44% to $5.0 million in 2025, then surged by 2823.77% to $144.9 million in 2026.
- Business Quant data shows SCLX's Cash & Equivalents at $144.9 million in Q1 2026, $5.0 million in Q4 2025, and $900000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 20.42 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 6.57 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 6.85 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 7.62 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 4.90 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 13.99 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3.18 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 976.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 4.17 Bn |
| 10 | Scilex Holding | 39.22 Mn | -73.57 Mn | 3.97 Mn | 112.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 144.87 Mn |
| Dec 31, 2025 | 4.96 Mn |
| Sep 30, 2025 | 900,000.00 |
| Jun 30, 2025 | 4.10 Mn |
| Mar 31, 2025 | 5.80 Mn |
| Dec 31, 2024 | 3.27 Mn |
| Sep 30, 2024 | 77,000.00 |
| Jun 30, 2024 | 6.89 Mn |
| Mar 31, 2024 | 1.80 Mn |
| Dec 31, 2023 | 3.92 Mn |
| Sep 30, 2023 | 1.95 Mn |
| Jun 30, 2023 | 34.10 Mn |
| Mar 31, 2023 | 5.10 Mn |
| Dec 31, 2022 | 2.18 Mn |
| Sep 30, 2022 | 34,961.00 |
| Jun 30, 2022 | 351,272.00 |
| Mar 31, 2022 | 250,000.00 |
| Dec 31, 2021 | 4.34 Mn |
| Sep 30, 2021 | 115,642.00 |
| Jun 30, 2021 | 257,621.00 |